AKT1 and melanoma: Statins, such as atorvastatin and lovastatin, inhibit the mevalonate (MVA) and cholesterol biosynthesis pathways, resulting in reduced programmed cell death ligand 1 (PD-L1) expression in melanoma cells via protein kinase B (AKT)- and β-catenin-dependent mechanisms.